Therapeutic Benefits of Tocilizumab Vary in Different Organs of a Patient with AA Amyloidosis

Systemic reactive AA amyloidosis is a life-threatening complication of chronic inflammatory diseases. Anti-interleukin-6 receptor, tocilizumab (TCZ), has been shown to improve clinical symptoms of patients with AA amyloidosis, accompanied with regression of the amyloid deposition. We report a case o...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsui, Masaru, Okayama, Satoshi, Tsushima, Hideo, Samejima, Kenichi, Kanki, Tomoko, Hasegawa, Ayako, Morimoto, Katsuhiko, Akai, Yasuhiro, Takano, Masato, Uemura, Shiro, Ohbayashi, Chiho, Saito, Yoshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145365/
https://www.ncbi.nlm.nih.gov/pubmed/25197587
http://dx.doi.org/10.1155/2014/823093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145365/
https://www.ncbi.nlm.nih.gov/pubmed/25197587
http://dx.doi.org/10.1155/2014/823093

Ejemplares similares